Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
Follow NIKI
Niki BioSolutions, Inc. (NIKI) Piotroski F-score
Niki BioSolutions, Inc.'s Piotroski F-score for fiscal 2023 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 3 in fiscal 2022.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 2 | (1.00) |
| FY2022 | 3 | (1.00) |
| FY2021 | 4 | (2.00) |
| FY2020 | 6 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (13.61%) | (45.82%) | Fail | 0 |
| Positive operating cash flow | (7.72m) | (12.32m) | Fail | 0 |
| Rising return on assets | (13.61%) | (45.82%) | Pass | 1 |
| Cash flow above net income | (4.90m) | (2.52m) | Fail | 0 |
| Falling long-term leverage | 0.15 | 0.02 | Fail | 0 |
| Rising current ratio | 1.18 | 0.57 | Pass | 1 |
| No new shares issued | 452,100 | 356,900 | Fail | 0 |
| Rising gross margin | 2.46% | 6.18% | Fail | 0 |
| Rising asset turnover | 0.02 | 0.06 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 4 |
| AIM AIM ImmunoTech Inc. compare | 3 |
| SYBX Synlogic, Inc. compare | 3 |
| NIKI Niki BioSolutions, Inc. | 2 |
| XCUR Exicure, Inc. compare | — |
| BCLI Brainstorm Cell Therapeutics Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| SKYE Skye Bioscience, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover